Advertisement
- United States
- /
- Medical Equipment
- /
- NasdaqCM:BMRA
Biomerica Third Quarter 2025 Earnings: US$0.061 loss per share (vs US$0.11 loss in 3Q 2024)
Biomerica (NASDAQ:BMRA) Third Quarter 2025 Results
Key Financial Results
- Revenue: US$1.12m (up 10.0% from 3Q 2024).
- Net loss: US$1.16m (loss narrowed by 39% from 3Q 2024).
- US$0.061 loss per share (improved from US$0.11 loss in 3Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Biomerica shares are up 18% from a week ago.
Risk Analysis
You still need to take note of risks, for example - Biomerica has 4 warning signs (and 3 which are significant) we think you should know about.
Valuation is complex, but we're here to simplify it.
Discover if Biomerica might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqCM:BMRA
Biomerica
A biomedical technology company, engages in developing, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide.
Adequate balance sheet with slight risk.
Similar Companies
Market Insights
Advertisement
Weekly Picks
ST
stuart_roberts on Unicycive Therapeutics ·
Looking to be second time lucky with a game-changing new product
Fair Value:US$21.5371.1% undervalued
31 followersusers have followed this narrative
0 commentsusers have commented on this narrative
5 likesusers have liked this narrative
HE
HegelBayeBagel on PlaySide Studios ·
PlaySide Studios: Market Is Sleeping on a Potential 10M+ Unit Breakout Year, FY26 Could Be the Rerate of the Decade
Fair Value:AU$0.8465.5% undervalued
7 followersusers have followed this narrative
1 commentusers have commented on this narrative
3 likesusers have liked this narrative
AN
AnimalDoctorKwon on Inotiv ·
Inotiv NAMs Test Center
Fair Value:US$1.275.7% undervalued
10 followersusers have followed this narrative
1 commentusers have commented on this narrative
3 likesusers have liked this narrative
TH
TheValueDetector on Cognyte Software ·
This isn’t speculation — this is confirmation.A Schedule 13G was filed, not a 13D, meaning this is passive institutional capital, not acti
Fair Value:US$95.6792.6% undervalued
6 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Recently Updated Narratives
CO
composite32 on Freehold Royalties ·
Freehold: Offers a fantastic growth-income intersection up to $50 WTI. Below $50 WTI, it may offer historic opportunities in terms of ROI.
Fair Value:CA$19.3811.9% undervalued
5 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
UN
unknown on Gold Fields ·
Beyond the "Value Trap"—Defending the $50 Intrinsic Floor
Fair Value:US$64.219.8% undervalued
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
UN
unknown on Taiwan Semiconductor Manufacturing ·
The "Geopolitical Discount" vs. The Monopolistic Floor: The Two Narratives of TSM
Fair Value:US$42814.9% undervalued
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Popular Narratives
DA
davidlsander on Ubisoft Entertainment ·
Is Ubisoft the Market’s Biggest Pricing Error? Why Forensic Value Points to €33 Per Share
Fair Value:€33.887.4% undervalued
59 followersusers have followed this narrative
5 commentsusers have commented on this narrative
25 likesusers have liked this narrative
TA
Talos on Tesla ·
The "Physical AI" Monopoly – A New Industrial Revolution
Fair Value:US$665.3638.3% undervalued
45 followersusers have followed this narrative
19 commentsusers have commented on this narrative
22 likesusers have liked this narrative
AN
AnalystConsensusTarget on Microsoft ·
Analyst Commentary Highlights Microsoft AI Momentum and Upward Valuation Amid Growth and Competitive Risks
Fair Value:US$603.2234.2% undervalued
1278 followersusers have followed this narrative
2 commentsusers have commented on this narrative
9 likesusers have liked this narrative
Trending Discussion
US
User on Tesla ·
This article completely disregards (ignores, forgets) how far China is in this field. If Tesla continues on this path, they will be fighting for their lives trying to sell $40000 dollar robots that can do less than a $10000 dollar one from China will do. Fair value of Tesla? It has always been a hype stock with a valuation completely unbased in reality. Your guess is as good as mine, but especially after the carbon credit scheme got canned, it is downwards of $150.
4
|0
US
User on Tesla ·
There is a lot of Musk's puffery being echoed in this article. "ecosystem dominance", Tesla certainly do not dominate any of their new markets. If Tesla is the undisputed leader of the premium "Closed Garden.", it is only through EV's and that business has been declining year-on-year, despite the market increasing. Vehicle manufactures are finding that customers are rejecting the subscription model. "The Cybercab fleet (launching 2026) acts as the financial bridge.", that is a stretch. Even if Level 4/5 autonomy is achieved, "profitability" still has to be proved, where the competition is not necessarily Waymo, but Uber. Taking the driver out of a ride‑hailing service may not be the killer saving people think it will be. Likewise, outside of CGI and for quite some time, an Optimus humanoid robot may prove more expensive and not as useful, versatile, skilled and knowledgeable as a domestic worker. Telsa may be withdrawing from the EV market, but for its other ventures, they have arrived late to the party, do not lead and show no sign that they will dominate any of them.
2
|0